TUMOR-SPECIFIC ANTI-EGFR ANTIBODY AND USE THEREOF Russian patent published in 2020 - IPC C07K16/30 C12N15/13 C07K16/46 C07K19/00 C12N15/62 C12N15/63 C12N5/10 A61K39/395 A61K48/00 A61P35/00 G01N33/574 

FIELD: biotechnology.

SUBSTANCE: described is a group of inventions comprising an antibody specifically recognizing expressed by tumor cells EGFRvIII or overexpressed EGFR, a nucleic acid, coding said antibody, an expression vector, a host cell, use of the antibody to produce a directional drug specifically targeted on tumor cells, use of the antibody to obtain an antibody-drug conjugate specifically targeted on tumor cells, use of the antibody to produce a multifunctional antibody, specifically targeted on tumor cells, using the antibody for producing a tumor diagnostic agent, using the antibody for producing an immune cell modified with a chimeric antigen receptor, immunoconjugate (versions), use of an immunoconjugate for preparing an anti-tumor agent, use of an immunoconjugate for producing a tumor diagnostic agent, use of an immunoconjugate for producing immune cells, modified with chimeric antigen receptor, chimeric antigen receptor, nucleic acid coding chimeric antigenic receptor, expression vector, virus for producing genetically modified immune cell, using a chimeric antigen receptor, or a nucleic acid, or an expression vector, or a virus for producing genetically modified immune cells, a genetically modified immune cell, aimed at tumor cells (versions), using genetically modified immune cells for preparing a tumor-inhibiting drug and a pharmaceutical composition for tumor inhibition.

EFFECT: invention extends the range of products specifically recognizing EGFRvIII or overexpressed EGFR expressed by tumor cells.

45 cl, 10 dwg, 13 tbl, 13 ex